# Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

> **NCT00050687** · PHASE1,PHASE2 · TERMINATED · sponsor: **Titan Pharmaceuticals**

## Conditions studied

- Prostatic Neoplasms
- Multiple Myeloma
- Bladder Neoplasms
- Lymphoma

## Interventions

- **DRUG:** Gallium maltolate

## Key facts

- **NCT ID:** NCT00050687
- **Lead sponsor:** Titan Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-06
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** — (—)
- **Last updated:** 2011-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050687, "Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00050687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*